COVID-19 Blog - Microbix

Microbix Schedules Release of Results for Q1 Fiscal 2024

Feb 7, 2024

Results Release and Webinar Discussion on Morning of February 14, 2024 MISSISSAUGA, CANADA, February 7, 2024 - Microbix Biosystems Inc....

Feb 6, 2024

FLOQSwab-formatted QAP Supporting MDx Tests for H. pylori MISSISSAUGA, CANADA, February 6, 2024 – Microbix Biosystems Inc. (TSX: MBX,...

Jan 3, 2024

Over C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency MISSISSAUGA, CANADA, January 3, 2024 – Microbix Biosystems Inc....

Dec 21, 2023

Full-Year Sales of $16.5 million and Net Loss of $0.04 million MISSISSAUGA, CANADA, December 21, 2023 - Microbix Biosystems Inc. (TSX:...

Dec 14, 2023

Expanded Collaboration to Improve Syndromic Infectious Disease Testing MISSISSAUGA, CANADA & IRVINE, CALIFORNIA, December 14, 2023 –...

Dec 7, 2023

Quality Controls for Respiratory Viral, Pharyngitis, and Genital Ulcer Disease Panels MISSISSAUGA, CANADA & BIRMINGHAM, ALABAMA,...

Dec 6, 2023

For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, CANADA, December 6, 2023 - Microbix Biosystems Inc. (TSX:...

Nov 17, 2023

Meetings with Growth-Oriented Investors, November 17 to 19, 2023 MISSISSAUGA, CANADA, November 17, 2023 - Microbix Biosystems Inc. (TSX:...

Nov 16, 2023

Sequel Pharma Reconfirms Kinlytic® urokinase Support for Catheter Clearance Indication MISSISSAUGA, CANADA, November 16, 2023 – Microbix...

Nov 10, 2023

Onboarding Tools and Quality Controls for Extended Genotype HPV Assays MISSISSAUGA, CANADA & TRIESTE, ITALY, November 10, 2023 –...